Identification of Medium-Length Antineurofilament Autoantibodies in Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe central nervous system disorder mediated by NMDAR antibodies that damages neurons. We investigated the correlation between cytoskeletal autoantibodies and the clinical severity in patients with anti-NMDAR encephalitis. Methods Non-NMDAR autoantibodies were identified by screening matched cerebrospinal fluid (CSF) and the serum samples of 45 consecutive patients with anti-NMDAR encephalitis and 60 healthy individuals against N-methyl-D-aspartate receptor 1-transfected and nontransfected human embryonic kidney 293T cells. Immunocytochemistry was performed to assess antibody binding in rat brain sections and primary cortical neurons. Cell-based assays and Western blotting were applied to identify autoantibodies targeting medium neurofilaments (NFMs). We compared clinical characteristics between patients with NMDAR encephalitis who were positive and negative for anti-NFM-autoantibodies. Results Anti-NFM autoantibodies were detected in both the serum and CSF in one patient (2%) and in the serum only in six patients (13%). No antibodies were detected in the serum of healthy controls (7/45 vs. 0/60, p=0.0016). Four of the seven patients with anti-NFM autoantibodies in serum were children (57%), and three (43%) had abnormalities in brain magnetic resonance imaging. These patients responded well to immunotherapy, and either no significant or only mild disability was observed at the last follow-up. Anti-NMDAR encephalitis did not differ with the presence of anti-NFM autoantibodies. Conclusions Anti-NFM autoantibodies may be present in patients with anti-NMDAR encephalitis, indicating underlying neuronal damage. A large cohort study is warranted to investigate the clinical differences between patients with NMDAR encephalitis according to their anti- NFM antibody status.
Abstract
Background and Purpose Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe central nervous system disorder mediated by NMDAR antibodies that damages neurons. We investigated the correlation between cytoskeletal autoantibodies and the clinical severity in patients with anti-NMDAR encephalitis. Methods Non-NMDAR autoantibodies were identified by screening matched cerebrospinal fluid (CSF) and the serum samples of 45 consecutive patients with anti-NMDAR encephalitis and 60 healthy individuals against N-methyl-D-aspartate receptor 1-transfected and nontransfected human embryonic kidney 293T cells. Immunocytochemistry was performed to assess antibody binding in rat brain sections and primary cortical neurons. Cell-based assays and Western blotting were applied to identify autoantibodies targeting medium neurofilaments (NFMs). We compared clinical characteristics between patients with NMDAR encephalitis who were positive and negative for anti-NFM-autoantibodies. Results Anti-NFM autoantibodies were detected in both the serum and CSF in one patient (2%) and in the serum only in six patients (13%). No antibodies were detected in the serum of healthy controls (7/45 vs. 0/60, p=0.0016). Four of the seven patients with anti-NFM autoantibodies in serum were children (57%), and three (43%) had abnormalities in brain magnetic resonance imaging. These patients responded well to immunotherapy, and either no significant or only mild disability was observed at the last follow-up. Anti-NMDAR encephalitis did not differ with the presence of anti-NFM autoantibodies. Conclusions Anti-NFM autoantibodies may be present in patients with anti-NMDAR encephalitis, indicating underlying neuronal damage. A large cohort study is warranted to investigate the clinical differences between patients with NMDAR encephalitis according to their anti- NFM antibody status.
참고문헌 (31)
- Dalmau J, "Anti-NMDA-receptor encephalitis : case series and analysis of the effects of antibodies", Lancet Neurol, 7, pp.1091~1098 (2008)
- Dalmau J, "Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis", Lancet Neurol, 10, pp.63~74 (2011)
- Granerod J, "Causes of encephalitis and differences in their clinical presentations in England : a multicentre, population-based prospective study", Lancet Infect Dis, 10, pp.835~844 (2010)
- Zhou J, "An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis", J Neuroimmunol, 320, pp.107~110 (2018)
- Dalmau J, "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma", Ann Neurol, 61, pp.25~36 (2007)
- Chapman MR, "Anti-NMDA receptor encephalitis : diagnosis, psychiatric presentation, and treatment", Am J Psychiatry, 168, pp.245~251 (2011)
- Wandinger KP, "AntiNMDA-receptor encephalitis : a severe, multistage, treatable disorder presenting with psychosis", J Neuroimmunol, 231, pp.86~91 (2011)
- Loughan AR, "Anti-N-methyl-D-aspartate receptor encephalitis : a review and neuropsychological case study", Clin Neuropsychol, 30, pp.150~163 (2016)
- Hughes EG, "Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis", J Neurosci, 30, pp.5866~5875 (2010)
- Shu Y, "Serum complement levels in anti-N-methyl-d-aspartate receptor encephalitis", Eur J Neurol, 25, pp.178~184 (2018)
- Al-Chalabi A, "Neurofilaments and neurological disease", Bioessays, 25, pp.346~355 (2003)
- Bartos A, "Lower serum antibodies against tau protein and heavy neurofilament in Alzheimer’s disease", J Alzheimers Dis, 64, pp.751~760 (2018)
- Bartos A, "Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis", J Neurol, 254, pp.20~25 (2007)
- Barro C, "Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis", Brain, 141, pp.2382~2391 (2018)
- Disanto G, "Serum neurofilament light : a biomarker of neuronal damage in multiple sclerosis", Ann Neurol, 81, pp.857~870 (2017)
- Piehl F, "Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod", Mult Scler, 24, pp.1046~1054 (2018)
- Matute-Blanch C, "Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome", Brain, 141, pp.1085~1093 (2018)
- Mariotto S, "Serum neurofilament light chain in NMOSD and related disorders : comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status", Mult Scler J Exp Transl Clin, 3, pp.2055217317743098~ (2017)
- Yilmaz A, "Neurofilament light chain protein as a marker of neuronal injury : review of its use in HIV-1 infection and reference values for HIVnegative controls", Expert Rev Mol Diagn, 17, pp.761~770 (2017)
- Bacioglu M, "Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases", Neuron, 91, pp.56~66 (2016)
- Oron L, "Animal model and in vitro studies of anti neurofilament antibodies mediated neurodegeneration in Alzheimer’s disease", J Neural Transm Suppl, 49, pp.77~84 (1997)
- Graus F, "A clinical approach to diagnosis of autoimmune encephalitis", Lancet Neurol, 15, pp.391~404 (2016)
- van Swieten JC, "Interobserver agreement for the assessment of handicap in stroke patients", Stroke, 19, pp.604~607 (1988)
- Liem RK, "Dysfunctions of neuronal and glial intermediate filaments in disease", J Clin Invest, 119, pp.1814~1824 (2009)
- Körtvelyessy P, "Biomarkers of neurodegeneration in autoimmune-mediated encephalitis", Front Neurol, 9, pp.668~ (2018)
- Martínez-Morillo E, "Neurofilament medium polypeptide(NFM)protein concentration is increased in CSF and serum samples from patients with brain injury", Clin Chem Lab Med, 53, pp.1575~1584 (2015)
- Kim OJ, "Neurofilament-M interacts with the D1 dopamine receptor to regulate cell surface expression and desensitization", J Neurosci, 22, pp.5920~5930 (2002)
- Kreye J, "Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis", Brain, 139, pp.2641~2652 (2016)
- Fiumelli H, "Phosphorylation of neurofilament subunit NF-M is regulated by activation of NMDA receptors and modulates cytoskeleton stability and neuronal shape", Cell Motil Cytoskeleton, 65, pp.495~504 (2008)
- Flanagan EP, "Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy : analysis of 102 patients", Ann Neurol, 81, pp.298~309 (2017)
- Fang B, "Autoimmune glial fibrillary acidic protein astrocytopathy : a novel meningoencephalomyelitis", JAMA Neurol, 73, pp.1297~1307 (2016)